Precigen Reports $54.978 Million Revenue in Q2 2026, Achieves Profitability

Precigen, Inc. reported significant financial improvements in its latest quarterly filing, with total revenues for the second quarter of 2026 reaching $54.978 million, a substantial increase from $856,000 in the same period last year. This growth was primarily driven by the commercial sales of Papzimeos, the company's FDA-approved immunotherapy for recurrent respiratory papillomatosis (RRP), which generated $53.070 million in product revenue. The company achieved profitability for the first time since its transformation into a healthcare company, posting a net income of $20.071 million compared to a net loss of $26.642 million in the prior year.

In terms of operational metrics, Precigen's total operating expenses for the quarter were $32.336 million, slightly down from $32.620 million a year earlier. The decrease was attributed to a significant reduction in research and development expenses, which fell by 36.6% to $7.282 million, as costs related to Papzimeos manufacturing transitioned from R&D to cost of goods sold following FDA approval. Selling, general, and administrative expenses increased by 37.9% to $22.249 million, reflecting the costs associated with the commercialization of Papzimeos.

The company also reported a notable increase in its cash position, with cash and cash equivalents totaling $16.329 million as of June 30, 2026, down from $30.234 million at the end of 2025. Precigen's total assets increased to $170.296 million, up from $155.505 million at the end of the previous fiscal year, driven by higher receivables and inventory levels. The company’s long-term debt remained stable at $93.880 million, reflecting its ongoing financial commitments.

Strategically, Precigen has focused on expanding its market presence following the FDA approval of Papzimeos in August 2025. The company has initiated commercial sales and is actively working on expanding its customer base, with no single customer accounting for more than 10% of total revenues in the latest quarter. Additionally, Precigen is pursuing international opportunities, having submitted a Marketing Authorization Application for Papzimeos to the European Medicines Agency.

Looking ahead, Precigen's management expressed optimism about the future, emphasizing that the successful commercialization of Papzimeos will be crucial for achieving sustained profitability. The company plans to leverage its proprietary technology platforms to advance additional product candidates and is exploring strategic partnerships to enhance its market position. However, management also acknowledged the inherent risks associated with launching a new product and the need for ongoing capital to support its operations and growth initiatives.